




Health Quality Innovation Network

MedsMatter! Conversation Series

CKD Medication Safety

August 26th, 2021

Health Quality Innovation Network



Logistics – Zoom Webinar



To ask a question, click on the **Chat** or **Q&A** icon.

Raise your hand if you want to verbally ask a question.

Resources and Recording from today's session will be sent out in within 24 hours.

You may adjust your audio by clicking **Audio Settings**.

You have been automatically muted with video turned off.

Purpose & Learning Objectives

CKD Medication Safety


- Review of medications that can lead to nephrotoxicity
- Learn how to reduce CKD patient risk factors
- Identify how to improve CKD patient medication safety

Today's Guest



Dr. Cate Rudder, PharmD
Kilgore's Medical Pharmacy
Columbia, Missouri

Pharmacist in Charge, PIC
Missouri Kidney Program





Chronic Kidney Disease: Know the Risks of Medications

Medications

Many commonly prescribed medications or their metabolites are excreted by the kidneys. Several can cause acute kidney injury (AKI), which can initiate or accelerate chronic kidney disease (CKD) progression.

Consider Kidney Function

- Consider the level of kidney function when prescribing medication
- Adjust dosage based on GFR to avoid complications
- Consider discontinuing medications that may cause AKI (RAAS blockers, NSAIDs, diuretics) or may cause complications during conditions which predispose to volume depletion and AKI (radio contrast studies, colonoscopy preparations, major surgery, or acute illness)
- Refer to the "Cautionary Notes" chart on the flip side of this card

30 East 33rd Street
New York, NY 10016
800.622.9010

Gadolinium-Containing Contrast

Gadolinium can put patients with severe CKD at risk for nephrogenic systemic fibrosis (NSF). A black box warning has been issued for gadolinium when GFR <30 ml/min/1.73 m².

Avoid Gadolinium

- Avoid gadolinium in patients with severe CKD
- When gadolinium is felt to be critical in patients with eGFR values of 15-30 ml/min/1.73 m² :
 - Consider lowest-dose macrocyclic compounds, as they have less association with NSF
 - Consider dialysis after gadolinium administration because it may help reduce NSF in patients with eGFR <15 ml/min/1.73 m² not yet on dialysis



Iodinated Radiocontrast

Use of iodinated radiocontrast media has been associated with AKI.

Balance the Risk of AKI

- Balance risk of AKI against diagnostic value and therapeutic implications.
- Recognize risk factors:
 - CKD (includes all stages, but especially people with GFR <30 ml/min/1.73 m²)
 - Age >70 years
 - Diabetes
 - Congestive heart failure
 - Volume depletion
 - Intra-arterial procedures
- Incorporate prevention:
 - Use of lowest dose of contrast
 - Volume repletion with intravenous saline or bicarbonate
 - Potential withdrawal of medications that could increase risk of AKI or complications (See “Cautionary Notes” chart on reverse.)
 - Check serum creatinine 48-96 hours after the procedure, since AKI occurs 48-72 hours after contrast

30 East 33rd Street
New York, NY 10016
800.622.9010

Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin-receptor blocker; CHF, congestive heart failure; CKD, chronic kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HTN, hypertension; NSAIDs, nonsteroidal anti-inflammatory drugs; NSF, nephrogenic systemic fibrosis; RAAS, renin-angiotensin-aldosterone system; SCr, serum creatinine.

Antihypertensives/cardiac medications

RAAS antagonists (ACE-I, ARB, aldosterone antagonist, direct renin inhibitor)	<ul style="list-style-type: none">• Use with caution in patients with renal artery stenosis• Start at lower dose in patients with GFR <45 ml/min/1.73 m²• Assess GFR and serum potassium a week after starting or escalating dose• Consider temporarily holding during IV contrast administration, or any potential cause of volume depletion (bowel preparation prior to colonoscopy, or acute illness)• Do not routinely discontinue when GFR <30 ml/min/1.73 m² as they remain nephroprotective
Beta-blockers	<ul style="list-style-type: none">• Reduce dose of hydrophilic beta-blockers (acebutolol, atenolol, bisoprolol, and nadolol) by 50% when GFR <30 ml/min/1.73m²
Digoxin	<ul style="list-style-type: none">• Reduce dose based on plasma



Analgesics

NSAIDS

- Avoid when GFR <30 ml/min/1.73 m²
- Prolonged therapy is not recommended when GFR <60 ml/min/1.73 m²
- Avoid when taking RAAS blocking agents or lithium

Opioids

- Reduce dose if GFR < 60 ml/min/1.73m²
- Use with caution in patients with GFR <15 ml/min/1.73 m²



Antimicrobials

Macrolides	<ul style="list-style-type: none">• Reduce dose by 50% when GFR <30 ml/min/1.73 m²
Fluoroquinolones	<ul style="list-style-type: none">• Reduce dose by 50% when GFR <15 ml/min/1.73 m²
Tetracyclines	<ul style="list-style-type: none">• Reduce dose when GFR <45 ml/min/1.73 m²; can exacerbate uremia
Antifungals	<ul style="list-style-type: none">• Reduce maintenance dose of fluconazole by 50% when GFR <45 ml/min/1.73 m²• Reduce dose of flucytosine when GFR <60 ml/min/1.73 m²
Trimethoprim	<ul style="list-style-type: none">• Reduce dose by 50% when GFR <30 ml/min/1.73 m²• Risk factors for hyperkalemia include high doses, the elderly, CKD, or with ACE-I and/or NSAIDs



Anticoagulants

Low-molecular-weight heparins

- Reduce dose by 50% when GFR <30 ml/min/1.73 m²
- Consider switch to conventional heparin or monitor plasma anti-factor Xa in those at high risk for bleeding

Warfarin

- Increased risk of bleeding when GFR <30 ml/min/1.73 m²



Hypoglycemics

Sulfonylureas

- Avoid mainly renally excreted agents (eg, glyburide/glibenclamide)
- Agents mainly metabolized by the liver may need reduced dose when GFR <30 ml/min/1.73 m² (eg, gliclazide, gliquidone)

Insulin

- Partly renally excreted and may need reduced dose when GFR <30 ml/min/1.73 m²

Metformin

- Avoid when GFR <30 ml/min/1.73 m², but consider risk-benefit if GFR is stable
- Review use when GFR <45 ml/min/1.73 m²
- Hold in patients during acute illness or prior to intravenous radiocontrast



Lipid-lowering

Statins

- No increased toxicity for simvastatin 20 mg/day when GFR <30 ml/min/1.73 m² or on dialysis
- Dose reduction/increased toxicity for GFR <30 ml/min/1.73m² for lovastatin, rosuvastatin, and pravastatin

Fenofibrate

- Associated with AKI



Miscellaneous

Lithium	<ul style="list-style-type: none"> • Nephrotoxic and may cause diabetes insipidus with prolonged use • Monitor GFR, electrolytes, and lithium levels every 6 months or more frequently if the dose increases or the patient is acutely ill • Avoid using NSAIDs • Maintain hydration during acute illness
Bisphosphonates	<ul style="list-style-type: none"> • Most are not recommended when GFR <30 ml/min/1.73 m² • Refer to bone specialist if GFR <30 ml/min/1.73 m² and no evidence of CKD-MBD (calcium, phosphate, alkaline phosphatase, and intact PTH normal)
Oral sodium phosphate-containing bowel preparations	<ul style="list-style-type: none"> • Can cause AKI by phosphate crystal deposition and volume depletion • Risk factors are CKD, >60 years of age, female gender, HTN, diabetes, CHF, volume depletion, active colitis, and medications that may predispose to AKI (RAAS blockers, diuretics, lithium, and NSAIDs)
Gabapentin	<ul style="list-style-type: none"> • Altered mental status, myoclonus and asterixis with severe CKD • GFR 30-59 ml/min/1.73m²: 200-700 mg bid, GFR 15-29 ml/min/1.73m²: 200-700 mg qd, GFR <15 ml/min/1.73m²: 300 every 2 d. • Extended release: GFR 30-59 ml/min/1.73m² : 600-1800 mg qd, GFR <30 ml/min/1.73m² – not recommended

Time for Q&A, Comments and Discussion



Resources

- [National Kidney Disease Education Program | NIDDK \(nih.gov\)](#)
- [NKF CKD Change package \(kidney.org\)](#)
- [KISU v7 i1 COVER.indd \(kdigo.org\)](#)
- [Chronic Kidney Disease Disparities: Educational Guide for Primary Care \(cms.gov\)](#)
- [Chronic Kidney Disease in the United States, 2021 \(cdc.gov\)](#)
- [Publications & Resources | Chronic Kidney Disease Initiative | CDC](#)
- [Kidney Basics | National Kidney Foundation](#)
- [Take Care of Your Kidneys and They Will Take Care of You. Chronic Kidney Disease. \(cdc.gov\)](#)
- [Review of Best Practices: Chronic Kidney Disease \(CKD\) Screening for Individuals with Diabetes | HQIN](#)
- [Kidney Disease: Prediction, Prevention, Protection - Show-Me ECHO \(showmeecho.org\)](#)
- [Managing Chronic Kidney Disease in Primary Care - ECHO \(viriniaprojectecho.org\)](#)

MedsMatter! Conversation Series

Save the Date:

11:30 p.m. CT/12:30 p.m. EST

September 23, 2021

Please complete the **evaluation** for this session listed in the Chat. We value your feedback!

FOR MORE INFORMATION

Call 877.731.4746 or visit www.hqin.org

Mary Ann Kimbel-RN, BAM

Quality Improvement Advisor

mkimbel@hqi.solutions

314-391-5566

www.hqi.solutions

Dr. Cate Rudder, PharmD

Kilgore's Medical Pharmacy

cate@kilgoresrx.com

866-345-6657

<https://kilgoresrx.com>

CONNECT WITH US

Call 877.731.4746 or visit www.hqin.org



@HQINetwork

Health Quality Innovation Network